NASDAQ:CFRX ContraFect (CFRX) Stock Forecast, Price & News $1.34 +0.04 (+3.08%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$1.30▼$1.3850-Day Range$0.90▼$2.3352-Week Range$0.90▼$363.20Volume69,679 shsAverage Volume2.59 million shsMarket Capitalization$2.10 millionP/E RatioN/ADividend YieldN/APrice Target$180.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ContraFect MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside13,388.8% Upside$180.75 Price TargetShort InterestHealthy4.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.75) to ($3.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 stars 3.4 Analyst's Opinion Consensus RatingContraFect has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $180.75, ContraFect has a forecasted upside of 13,388.8% from its current price of $1.34.Amount of Analyst CoverageContraFect has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.62% of the float of ContraFect has been sold short.Short Interest Ratio / Days to CoverContraFect has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ContraFect has recently increased by 140.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldContraFect does not currently pay a dividend.Dividend GrowthContraFect does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CFRX. Previous Next 2.0 News and Social Media Coverage News SentimentContraFect has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ContraFect this week, compared to 2 articles on an average week.Search InterestOnly 15 people have searched for CFRX on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ContraFect to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ContraFect insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of ContraFect is held by insiders.Percentage Held by InstitutionsOnly 27.34% of the stock of ContraFect is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ContraFect are expected to grow in the coming year, from ($6.75) to ($3.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ContraFect is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ContraFect is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About ContraFect (NASDAQ:CFRX) StockContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.Read More Receive CFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter. Email Address CFRX Stock News HeadlinesMay 28, 2023 | americanbankingnews.comContraFect (NASDAQ:CFRX) Downgraded to Sell at StockNews.comMay 28, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for ContraFect Co. Raised by Analyst (NASDAQ:CFRX)June 1, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 23, 2023 | finance.yahoo.comCFRX: First Patient Dosed in Phase 1b/2 Trial of Exebacase for the Treatment of Chronic Prosthetic Joint Infections…May 20, 2023 | americanbankingnews.comStockNews.com Lowers ContraFect (NASDAQ:CFRX) to SellMay 15, 2023 | finanznachrichten.deContraFect Corporation: ContraFect Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 15, 2023 | finance.yahoo.comContraFect Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 12, 2023 | americanbankingnews.comContraFect (NASDAQ:CFRX) Raised to "Hold" at StockNews.comJune 1, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 11, 2023 | americanbankingnews.comContraFect Co. (NASDAQ:CFRX) Sees Significant Increase in Short InterestApril 27, 2023 | finance.yahoo.comWhat's Going On With ContraFecta Stock TodayApril 27, 2023 | americanbankingnews.comContraFect Co. (NASDAQ:CFRX) Short Interest UpdateApril 26, 2023 | finance.yahoo.comContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the KneeApril 20, 2023 | finance.yahoo.comContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative PathogensApril 18, 2023 | investorplace.comWhy Is ContraFect (CFRX) Stock Down 14% Today?April 18, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for ContraFect Co.'s FY2023 Earnings (NASDAQ:CFRX)April 14, 2023 | americanbankingnews.comContraFect (NASDAQ:CFRX) Upgraded by Maxim Group to BuyApril 14, 2023 | americanbankingnews.comContraFect Co. (NASDAQ:CFRX) to Post Q1 2023 Earnings of ($10.83) Per Share, Zacks Small Cap ForecastsApril 13, 2023 | markets.businessinsider.comMaxim Group upgrades ContraFect (CFRX) to a BuyApril 13, 2023 | finance.yahoo.comCFRX: Initiates Phase 1 Trial for Exebacase in Chronic Prosthetic Joint Infection…April 12, 2023 | benzinga.comIs ContraFect Corp (CFRX) a Bad Choice in Biotechnology Monday?April 6, 2023 | finance.yahoo.comContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID MeetingApril 5, 2023 | americanbankingnews.comContraFect (NASDAQ:CFRX) Upgraded by StockNews.com to SellApril 1, 2023 | finanznachrichten.deContraFect Corporation: ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business UpdateMarch 31, 2023 | finance.yahoo.comContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business UpdateMarch 21, 2023 | americanbankingnews.comContraFect (CFRX) Set to Announce Quarterly Earnings on WednesdayFebruary 28, 2023 | finance.yahoo.comContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private PlacementSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter. Email Address CFRX Company Calendar Last Earnings3/31/2023Today5/31/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFRX CUSIPN/A CIK1478069 Webwww.contrafect.com Phone(914) 207-2300FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Stock Price Forecast$180.75 High Stock Price Forecast$560.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+13,593.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($88.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,150,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-933.14% Return on Assets-176.53% Debt Debt-to-Equity RatioN/A Current Ratio0.90 Quick Ratio0.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.00) per share Price / Book-0.66Miscellaneous Outstanding Shares1,570,000Free Float1,538,000Market Cap$2.07 million OptionableNot Optionable Beta0.44 Key ExecutivesRoger J. PomerantzChairman, President & Chief Executive OfficerMichael MessingerChief Financial OfficerRaymond SchuchVice President-ResearchGary WoodnuttSenior Vice President-Translational ServicesMatthew SalamoneVice President-Human ResourcesKey CompetitorsOncoSec MedicalNASDAQ:ONCSSoligenixNASDAQ:SNGXSciSparcNASDAQ:SPRCAyala PharmaceuticalsNASDAQ:ADXSNovaBay PharmaceuticalsNYSE:NBYView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 4,009,150 shares on 5/16/2023Ownership: 5.492%State Street CorpSold 102,598 shares on 5/16/2023Ownership: 1.738%Acadian Asset Management LLCSold 1,537,752 shares on 5/11/2023Ownership: 3.260%Virtu Financial LLCSold 257,714 shares on 5/1/2023Ownership: 0.862%Simplex Trading LLCSold 12,000 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions CFRX Stock - Frequently Asked Questions Should I buy or sell ContraFect stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last twelve months. There are currently 2 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CFRX shares. View CFRX analyst ratings or view top-rated stocks. What is ContraFect's stock price forecast for 2023? 4 analysts have issued twelve-month price targets for ContraFect's shares. Their CFRX share price forecasts range from $3.00 to $560.00. On average, they expect the company's stock price to reach $180.75 in the next year. This suggests a possible upside of 13,593.2% from the stock's current price. View analysts price targets for CFRX or view top-rated stocks among Wall Street analysts. How have CFRX shares performed in 2023? ContraFect's stock was trading at $7.68 at the start of the year. Since then, CFRX stock has decreased by 82.8% and is now trading at $1.32. View the best growth stocks for 2023 here. Are investors shorting ContraFect? ContraFect saw a increase in short interest in May. As of May 15th, there was short interest totaling 166,000 shares, an increase of 140.9% from the April 30th total of 68,900 shares. Based on an average daily volume of 3,970,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 4.6% of the company's stock are sold short. View ContraFect's Short Interest. When is ContraFect's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our CFRX earnings forecast. How were ContraFect's earnings last quarter? ContraFect Co. (NASDAQ:CFRX) announced its earnings results on Friday, March, 31st. The biotechnology company reported ($16.14) earnings per share (EPS) for the quarter. When did ContraFect's stock split? ContraFect's stock reverse split before market open on Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX). What is ContraFect's stock symbol? ContraFect trades on the NASDAQ under the ticker symbol "CFRX." Who are ContraFect's major shareholders? ContraFect's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (5.49%), Acadian Asset Management LLC (3.26%), State Street Corp (1.74%), Virtu Financial LLC (0.86%), Simplex Trading LLC (0.00%) and FNY Investment Advisers LLC (0.00%). View institutional ownership trends. How do I buy shares of ContraFect? Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ContraFect's stock price today? One share of CFRX stock can currently be purchased for approximately $1.32. How much money does ContraFect make? ContraFect (NASDAQ:CFRX) has a market capitalization of $2.07 million. The biotechnology company earns $-65,150,000.00 in net income (profit) each year or ($88.03) on an earnings per share basis. How can I contact ContraFect? ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The official website for the company is www.contrafect.com. The biotechnology company can be reached via phone at (914) 207-2300 or via email at mmessinger@contrafect.com. This page (NASDAQ:CFRX) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraFect Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.